Delivra Health Brands (DHB) Q3 2025 earnings summary

Executive summary

• Achieved 3% year-over-year revenue growth and positive adjusted EBITDA for Q3 2025, driven by strong marketing and expanded product offerings.

• Launched new Dream Water Sleep Shot and Gummies in Canada, expanding reach in retail and travel channels.

• LivRelief's "Quiets Chronic Pain" campaign led to a 21% year-over-year increase in units sold.

Financial highlights

• Net revenue for the nine months ended March 31, 2025, was $9,012,000, up 3% from $8,792,000 year-over-year.

• Gross profit for the nine months was $4,444,000 with a gross margin of 49%, down from 52% last year due to higher cost of sales.

• Adjusted EBITDA for the nine months was $(51,000), down from $845,000 last year, reflecting increased marketing investment.

• For Q3 2025, net revenue was $3,095,000, up 1% year-over-year; gross profit was $1,552,000 with a 50% margin.

• Q3 2025 Adjusted EBITDA was $124,000, down from $246,000 in Q3 2024 due to higher marketing spend.

Outlook and guidance

• Management expects continued growth, with Q3 results laying a strong foundation for Q4 and fiscal 2026.

• New go-to-market strategy for LivRelief Infused channel to be implemented in fiscal 2026.